Defying the Odds: Small Cell Lung Cancer with Essential Thrombocythemia and Secondary Cancers
- PMID: 40672006
- PMCID: PMC12264305
- DOI: 10.7759/cureus.86093
Defying the Odds: Small Cell Lung Cancer with Essential Thrombocythemia and Secondary Cancers
Abstract
Small cell lung cancer (SCLC) is an aggressive malignancy with historically poor survival outcomes, especially in patients with significant comorbidities. This report presents a rare case of a 65-year-old woman with limited-stage SCLC and JAK2-positive essential thrombocythemia (ET), who subsequently developed multiple malignancies including papillary thyroid carcinoma, right-sided colon adenocarcinoma, and basal cell carcinoma. Despite serious complications such as subdural hematoma and intra-abdominal bleeding, the patient remains clinically stable over a decade after her initial diagnosis. Genetic testing revealed no hereditary cancer syndromes, suggesting a potential role of chronic inflammation and prior therapies in her cancer trajectory. This case underscores the importance of early aggressive therapy, vigilant long-term follow-up, and multidisciplinary coordination in managing complex oncologic and hematologic conditions.
Keywords: essential thrombocythemia; jak2 mutation; myeloproliferative neoplasm; secondary malignancies; small cell lung cancer.
Copyright © 2025, George et al.
Conflict of interest statement
Human subjects: All authors have confirmed that this study did not involve human participants or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Figures
Similar articles
-
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.J Thorac Oncol. 2011 Feb;6(2):244-85. doi: 10.1097/JTO.0b013e318206a221. J Thorac Oncol. 2011. PMID: 21252716 Free PMC article.
-
Systemic Inflammatory Response Syndrome.2025 Jun 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jun 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31613449 Free Books & Documents.
-
Management of urinary stones by experts in stone disease (ESD 2025).Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085. Epub 2025 Jun 30. Arch Ital Urol Androl. 2025. PMID: 40583613 Review.
-
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100. Epidemiol Prev. 2013. PMID: 23851286 Italian.
-
Refractory small cell lung cancer with pancreatic metastasis: A case report.Medicine (Baltimore). 2025 Jan 10;104(2):e41167. doi: 10.1097/MD.0000000000041167. Medicine (Baltimore). 2025. PMID: 39792773 Free PMC article.
References
-
- Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. Turrisi AT 3rd, Kim K, Blum R, et al. N Engl J Med. 1999;340:265–271. - PubMed
-
- Small cell lung cancer. Kalemkerian GP, Akerley W, Bogner P, et al. https://pubmed.ncbi.nlm.nih.gov/23307984/ J Natl Compr Canc Netw. 2013;11:78–98. - PMC - PubMed
-
- Essential thrombocythemia. Tefferi A, Pardanani A. N Engl J Med. 2019;381:2135–2144. - PubMed
-
- Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Hasselbalch HC. Blood. 2012;119:3219–3225. - PubMed
-
- Durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Paz-Ares L, Dvorkin M, Chen Y, et al. Lancet. 2019;394:1929–1939. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous